found statistically significant associations between pain VAS and depression score, impacts of pain on daily behaviors and between pain VAS and DAS-28. Conclusions: Almost 40% of patients had moderate to severe pain in a population of severe RA followed in hospital centers and treated with biotherapies in more than 80% of cases. Therefore, pain is still a major outcome to consider in RA. But, the proportion of patients with moderate to severe pain is less important than that one published by Taylor et al. Pain is associated with the DAS-28 score, but also with the depression score.
SAT0125 TENOSYNOVITIS IN RHEUMATOID ARTHRITIS: PREVALENCE AND DETERMINANTS OF TENOSYNOVITIS DETECTED IN THE SONAR-ULTRASOUND EXAMINATION IN THE SCQM COHORT
Objectives: The aim of this study was to assess the prevalence and determinants of TS detected in the SONAR (Swiss Sonography Group in Arthritis and Rheumatism) examinations in patients with Rheumatoid Arthritis in the SCQM Cohort. Methods: The SONAR ultrasound examination consists of a semi-quantitative score employing both multiplanar gray scale (B-mode) and Doppler-mode (PwD) and a TS composite score (grade 0-3). Pathologic TS was defined as TS grade 2-3. Characteristics of patients with and without TS are shown using standard descriptive methods. In a longitudinal sub-group the change in TS from no TS to pathologic TS or vice versa and DAS28 over time was categorized as "worse" ( DAS28 ≥2.1), "same" and "better" ( DAS28 ≤-2.1) and the correlation between change DAS28 and in tenosynovitis was evaluated. Results: 941 RA patients with TS score were available. 20% of included patients showed signs of TS. The presence of TS was associated with male gender and higher values of disease activity and physical function disability. Furthermore, 15% of patients in DAS28 Remission had sonographic TS. TS was less frequently observed in patients on biologic therapies (Table 1 ). The longitiudinal sub-group consisted of 348 patients. The correlation between change in DAS28 and change in TS was poor (polychoric correlation 0.28 [0.14, 0.43]). 
Background:
The association between physical functioning and rheumatoid arthritis (RA) disease activity is well established. In randomized controlled trials (RCTs) of RA treatment, reductions in disease activity result in improved physical functioning. The mental health benefits associated with reductions in disease activity are less well recognized. Objectives: Investigate the association between reductions in RA disease activity and measures of mental health status. Methods: A systematic review of the published literature of RCTs in RA was conducted. The search was limited to those published in the last 10 years that included the Short-Form (SF)-36 Health Survey as an outcome measure. Results: The search strategy yielded 77 articles of which 38 were excluded for the following reasons: not RCT (23); focus exclusively on early RA (9); psychometric evaluation (4); review study (1) ; and off topic (1) . Of the 39 articles reporting mean changes in scores on the SF-36 mental health (MH) and role emotional (RE) domains by treatment group, 3 articles also presented these changes in association with reductions in RA disease activity measures. [1] [2] [3] In relation to American College of Rheumatology (ACR) response criteria, small to moderate (0.2-0.5 standard deviation [SD]) effect size changes in RE and MH domain scores were observed among RA patients whose ACR responses ranged from 20-49%. Moderate to large effect sizes (0.5-0.8 SD) were reported in RE and MH domain change scores among ACR50 responders. Similar changes in RE and MH domain scores were reported by patients with reductions in Simplified Disease Activity Index (SDAI) of ≥10 points. Conclusions: The benefits of clinically meaningful reductions in disease activity among RA patients not only include improved physical functioning but also meaningful improvements in overall mental health status. The improvement in mental health is positively associated with reduction in disease activity, with only small to moderate improvements associated with less than ACR50 responses. Additional work is needed to investigate the incremental effects of RA therapies on mental health beyond the effects related to improvements in disease activity.
